Innovation Pharmaceuticals Inc (IPIX)

[Floelygazouc]

Dear Shareholders,

Innovation Pharmaceuticals (“IPIX”) is pleased to announce that it has completed enrollment in its Phase 2 clinical trial of Brilacidin for the prevention of Severe Oral Mucositis (OM). Shareholders should be proud for helping develop this drug and accomplishing this milestone.

An estimated 500,000 people in the United States suffer from this painful and debilitating condition that disrupts continuity of care and leads to costly complications. Sixty-two percent of OM sufferers require hospitalization and 70 percent with Grade 3 or Grade 4 OM require feeding tube insertion. In its most severe forms, OM can be life-threatening, as food and water intake of affected patients is compromised.

In conjunction with the press release, the Company has posted a new blog, accessible at the link below, which goes into greater depth as to the major unmet medical need and considerable market opportunity in not just treating, but in preventing, Severe OM. Brilacidin, Innovation Pharmaceuticals’ first-in-class immunomodulatory drug candidate with dual anti-inflammatory and anti-bacterial properties, represents a potential OM treatment currently in mid-stage development.

Topline results for the Phase 2 trial of Brilacidin in the prevention of Severe OM are anticipated in 4Q2017.